Trevi Therapeutics to Report Second Quarter 2026 Financial Results and Provide a Corporate Update on August 6, 2026

Rhea-AI Summary

Trevi Therapeutics (Nasdaq: TRVI) announced that senior management will host a conference call and live audio webcast on Thursday, August 6, 2026, at 4:30 p.m. ET. The event will provide a corporate update and review Trevi’s second quarter 2026 financial results for the period ended June 30, 2026.

Trevi is a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio (oral nalbuphine ER) for chronic cough in patients with idiopathic pulmonary fibrosis (IPF), non-IPF interstitial lung disease (non-IPF ILD), and refractory chronic cough (RCC). According to the company, registration and access details are available in the Investors & News section of its website, with a webcast replay accessible for 30 days.

Market Context

Tag-specific history shows an average move of 0.46% across three earnings-date notices. That record ...

Analysis

Tag-specific history shows an average move of 0.46% across three earnings-date notices. That record frames this scheduling release as an information-timing event; the pending financial results remain the key item to watch, with moderate short positioning as a risk factor.

Key Figures

Announcement date: July 30, 2026 Results date: August 6, 2026 Conference call time: 4:30 p.m. ET +2 more

5 metrics

Announcement date July 30, 2026 Article publication date

Results date August 6, 2026 Second-quarter 2026 financial results and corporate update

Conference call time 4:30 p.m. ET August 6, 2026 conference call and webcast

Quarter end June 30, 2026 Financial results period under review

Webcast replay 30 days Replay availability following the event

Previous Earnings date Reports

3 past events · Latest: Apr 28 (Neutral)

Same Type Pattern 3 events

Date	Event	Sentiment	24h Move	Catalyst
Apr 28	Earnings-date notice	Neutral	-0.1%	Scheduled first-quarter results and corporate update for May 5, 2026
Mar 10	Earnings-date notice	Neutral	+1.5%	Scheduled fourth-quarter and year-end 2025 results for March 17, 2026
Nov 06	Earnings-date notice	Neutral	+0.0%	Scheduled third-quarter 2025 results and corporate update for November 13

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Tag-specific earnings-date notices showed mixed reactions: -0.14%, +1.53%, and 0%, averaging +0.46%.

Key Terms

idiopathic pulmonary fibrosis, interstitial lung disease, refractory chronic cough

3 terms

idiopathic pulmonary fibrosis medical

"for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis"

Idiopathic pulmonary fibrosis is a chronic lung disease in which the air‑carrying tissue becomes progressively thickened and scarred for no identifiable reason, making the lungs stiff and less able to move oxygen—similar to a sponge that hardens and loses its pores. It matters to investors because it is life‑limiting with limited effective treatments, so clinical trial outcomes, regulatory approvals, pricing and reimbursement decisions can strongly affect the commercial value of therapies and the financial prospects of companies developing treatments.

interstitial lung disease medical

"non-IPF interstitial lung disease (non-IPF ILD)"

A group of lung conditions that cause inflammation and scarring of the thin tissue between the air sacs, which makes it harder for oxygen to pass into the blood; imagine the lungs’ fine filters becoming stiff and less effective. Investors care because reports of interstitial lung disease can affect a drug’s safety profile, trigger regulatory warnings or label changes, and shift demand for treatments or create liability risks that influence a company’s valuation.

refractory chronic cough medical

"and refractory chronic cough (RCC)"

A refractory chronic cough is a long-lasting cough that persists despite standard medical evaluation and treatment, typically lasting eight weeks or more and not improving with usual therapies. Investors should care because it represents a clear unmet medical need that can drive demand for new drugs, devices, or diagnostics—similar to a stubborn problem customers keep returning to a store for until a better solution appears—affecting market potential and regulatory attention.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Conference call and webcast to be held at 4:30 p.m. ET

NEW HAVEN, Conn., July 30, 2026 (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF), non-IPF interstitial lung disease (non-IPF ILD), and refractory chronic cough (RCC), today announced that senior management will host a conference call and live audio webcast on Thursday, August 6, 2026, at 4:30 p.m. ET, to provide a corporate update and review the Company's financial results for the quarter ended June 30, 2026. 

Conference Call and Webcast
To register for the live conference call and webcast, please visit the ‘Investors & News’ section of the Company’s website or access directly at ir.trevitherapeutics.com/news-events/events. Please note for phone participants: Once registered, you will receive an email with unique call-in details. An archived replay of the webcast will also be available for 30 days on the Company's website following the event.

About Trevi Therapeutics, Inc.       
Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine extended-release) for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF), non-IPF interstitial lung disease (non-IPF ILD), and refractory chronic cough (RCC). In clinical trials, Haduvio showed a statistically-significant reduction in cough frequency, consistent across baseline cough frequencies and showed improvements in patient-reported outcomes, in both patients with IPF-related chronic cough and in patients with RCC. Haduvio is believed to act on the cough reflex arc both centrally and peripherally as a kappa agonist and a mu antagonist (KAMA), targeting opioid receptors that play a key role in controlling chronic cough. Nalbuphine is not currently scheduled by the U.S. Drug Enforcement Agency.   

Chronic cough in patients with IPF and non-IPF ILD is a condition with high unmet need and no FDA-approved therapies. There are ~140,000 U.S. patients with IPF, and two-thirds of these patients are faced with uncontrolled chronic cough. Additionally, there are ~228,000 U.S. patients with non-IPF ILD, with 50-60% having uncontrolled chronic cough. The impact of chronic cough is significant, with patients coughing up to 1,500 times per day. This consistent cough, and any associated damage, may lead to a higher risk of morbidity and mortality, including worsening disease, a higher risk of progression, increased respiratory hospitalizations, and a decline in patients' quality of life.       
    
RCC is a condition with high unmet need and no FDA-approved therapies. RCC is defined as a persistent cough lasting >8 weeks despite treatment for an underlying condition (i.e., asthma, gastroesophageal reflux disease, non-asthmatic eosinophilic bronchitis, upper airway cough syndrome, or post-nasal drip) and includes unexplained chronic cough. There are ~2-3 million U.S. patients with RCC, and it is believed to be associated with cough reflex hypersensitivity involving both the central and peripheral nervous systems. RCC is highly debilitating and may impact patients physically, psychologically, and socially. 

Trevi intends to propose Haduvio as the trade name for oral nalbuphine ER. Its safety and efficacy have not been evaluated by any regulatory authority.    
    
For more information, visit www.TreviTherapeutics.com and follow Trevi on X (formerly Twitter) and LinkedIn.

Investor Contact     
Jonathan Carlson     
Trevi Therapeutics, Inc.     
(203) 654 3286     
IR@trevitx.com  
  
Media Contact     
Rosalia Scampoli     
914-815-1465     
rscampoli@marketcompr.com     

FAQ

When will Trevi Therapeutics (NASDAQ: TRVI) report its Q2 2026 financial results?

Trevi Therapeutics will review its Q2 2026 financial results on August 6, 2026, at 4:30 p.m. ET. According to the company, this will occur during a combined corporate update conference call and live audio webcast for investors.

How can investors access the Trevi Therapeutics (TRVI) Q2 2026 earnings conference call and webcast?

Investors can register for Trevi Therapeutics’ Q2 2026 conference call and webcast via the Investors & News section of its website. According to the company, registrants receive unique call-in details by email, and the live audio webcast is accessible online.

Will a replay be available for the Trevi Therapeutics (TRVI) August 6, 2026 earnings webcast?

Yes, a replay of Trevi Therapeutics’ August 6, 2026 webcast will be available for 30 days on the company’s website. According to the company, the archived audio can be accessed through the Investors & News events page following the live event.

What topics will Trevi Therapeutics cover during the August 6, 2026 TRVI investor call?

Trevi Therapeutics will provide a corporate update and review financial results for the quarter ended June 30, 2026. According to the company, senior management will host the call and webcast for investors and analysts.

What does Trevi Therapeutics (TRVI) develop and how is Haduvio described?

Trevi Therapeutics is a clinical-stage biopharmaceutical company developing Haduvio (oral nalbuphine ER). According to the company, Haduvio is an investigational therapy targeting chronic cough in idiopathic pulmonary fibrosis, non-IPF interstitial lung disease, and refractory chronic cough.